Scarica l'app Stockscreener
21.92
5.79%
1.20
Dopo l'orario di chiusura:
21.70
-0.22
-1.00%
Precedente Chiudi:
$20.72
Aprire:
$21.11
Volume 24 ore:
207.35K
Relative Volume:
0.71
Capitalizzazione di mercato:
$715.56M
Reddito:
-
Utile/perdita netta:
$-29.59M
Rapporto P/E:
-17.19
EPS:
-1.275
Flusso di cassa netto:
$-18.35M
1 W Prestazione:
+8.41%
1M Prestazione:
-8.36%
6M Prestazione:
+189.95%
1 anno Prestazione:
+261.12%
Intervallo 1D:
$21.04
$22.00
Intervallo di 1 settimana:
$19.55
$22.00
Portata 52W:
$5.55
$29.27
Nuvectis Pharma Inc Stock (NVCT) Company Profile
Nome
Nuvectis Pharma Inc
Settore
Industria
Telefono
360-837-7232
Indirizzo
1 BRIDGE PLAZA, SUITE 275, FORT LEE
Compare NVCT vs VRTX, MRNA, REGN, ARGX, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
NVCT
Nuvectis Pharma Inc
|
21.92 | 660.06M | 0 | -29.59M | -18.35M | -1.275 |
VRTX
Vertex Pharmaceuticals Inc
|
504.73 | 133.37B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
190.01 | 79.40B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
735.20 | 81.13B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
919.21 | 60.03B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
206.64 | 43.93B | 742.00K | -1.37B | -1.07B | -7.0731 |
Nuvectis Pharma Inc Stock (NVCT) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-04-02 | Iniziato | Maxim Group | Buy |
| 2025-03-17 | Iniziato | Laidlaw | Buy |
| 2022-07-13 | Iniziato | Ladenburg Thalmann | Buy |
Nuvectis Pharma Inc Borsa (NVCT) Ultime notizie
Roth Capital raises Nuvectis target to $33 - scanx.trade
(NVCT) and the Role of Price-Sensitive Allocations - Stock Traders Daily
Nuvectis Pharma Earns Breakthrough Therapy Status in China for Brain Cancer Treatment NXP200 - Kalkine Media
Nuvectis' In-Licensed Cancer Drug Earned Breakthrough Designation in China, and It's Not Even Their Lead - benzinga.com
NVCT Stock Price, Quote & Chart - ChartMill
Nuvectis' In-Licensed Cancer Drug Earned Breakthrough Designation In China, And It's Not Even Their Lead Asset - Mena FN
Nuvectis’ NXP200 receives breakthrough therapy status in China By Investing.com - Investing.com Canada
Nuvectis Pharma's NXP200 Granted Breakthrough Therapy Designation in China for High-Grade Glioma - marketscreener.com
Nuvectis’ NXP200 receives breakthrough therapy status in China - Investing.com
Nuvectis Announces NXP200 Granted Breakthrough Therapy - GlobeNewswire
Nuvectis Pharma (NVCT) Short Interest & Short Float | Updated Sep 2026 - MarketBeat
Nuvectis Pharma (Nasdaq:NVCT)Stock Analysis - Simply Wall Street
Nuvectis Pharma (NVCT) Climbs 2.90% to $22.00 as Buyers Approach ResistanceExtension Target - siam.in
Nuvectis Pharma: Haisco Licensing Deal Revitalizes BiotechBut No Rush To Invest Today - Seeking Alpha
Nuvectis Pharma at H.C. Wainwright conference: pipeline and cash stand out - Investing.com Canada
NVCT: Strong clinical progress and financial position drive near-term catalysts in precision medicine - TradingView
Nuvectis at Cantor healthcare conference: betting on factor B By Investing.com - Investing.com Canada
NVCT: NXP100's once-daily dosing and strong efficacy position it to disrupt the PNH market - TradingView
Nuvectis at Cantor healthcare conference: betting on factor B - investing.com
NVCT: NXP100's once-daily dosing and strong PNH data position it for pivotal U.S. trials and expansion - tradingview.com
Nuvectis Pharma, Inc. (NVCT) Stock Price & News - Syfe
(NVCT) as a Liquidity Pulse for Institutional Tactics - Stock Traders Daily
Nuvectis Pharma To Participate in Upcoming Investor Conferences - Investing News Network
Nuvectis Pharma plans two September talks, both available online - Stock Titan
Some of the Top Biotech Funds Just Bought Into This Under-the-Radar Biotech (NASDAQ: NVCT) - Benzinga
Nuvectis Pharma (NVCT) Rises 3.75% to $23.93, Pressing Against Key ResistanceHigh Volume Stocks - vinanet.vn
Lucid Capital Markets initiates Nuvectis Pharma stock with buy rating By Investing.com - Investing.com UK
Nuvectis Pharma Inc (NVCT) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Nuvectis Pharma, Inc. SEC Filing (Aug 31, 2026) - Stock Titan
Wall Street Analysts Believe Nuvectis Pharma (NVCT) Could Rally 62.5%: Here's is How to Trade - qz.com
Wall Street Analysts Predict a 56.41% Upside in Nuvectis Pharma (NVCT): Here's What You Should Know - easternprogress.com
Nuvectis Pharma Launches New $200 Million ATM Program - TipRanks
Nuvectis Pharma (Nasdaq: NVCT) sets at-the-market stock sales capacity - Stock Titan
Nuvectis Pharma (NASDAQ: NVCT) sets at-the-market share sales via Jefferies - Stock Titan
Nuvectis (NVCT): Moves 0.26% Down to $23.29; Boundary Watch: $22.13 and $24.45 Define the Nearby Reference Levels in the Latest SessionProfit Surge Picks - vinanet.vn
We're Not Very Worried About Nuvectis Pharma's (NASDAQ:NVCT) Cash Burn Rate - Sahm
Nuvectis (NVCT) Quarterly Scorecard: EPS Misses Its Estimate at the Close; Trading Response: Shares Finish 0.09% Higher on the DayManagement Guidance Update - dars.gov.et
Nuvectis Stock Surges Around 97% in 3 Months: Here's Why - Yahoo Finance
Zacks Investment Research - גלובס
Nuvectis Pharma (NASDAQ:NVCT) Trading 6.2% HigherWhat's Next? - MarketBeat
Nuvectis Pharma (NVCT) Slips 1.4% to $18.96 as Shares Approach Key Support LevelALMA Signal - vinanet.vn
Behavioral Patterns of NVCT and Institutional Flows - Stock Traders Daily
NVCT Q2 2026 Earnings: Wider-than-Expected Loss as Clinical Pipeline ProgressesInvestor Earnings Call - vinanet.vn
Nuvectis Pharma (NASDAQ:NVCT) Shares Gap UpWhat's Next? - MarketBeat
NVCT Q2 2026 Earnings: Wider-than-Expected Loss Reflects Continued R&D InvestmentPre-Earnings Setup - vinanet.vn
NVCT Q2 2026 Earnings: Wider-Than-Expected Loss Highlights Clinical-Stage Investment PhaseShort-Term Outlook - dars.gov.et
Certain Stock Options of Nuvectis Pharma, Inc. are subject to a Lock-Up Agreement Ending on 13-AUG-2026. - marketscreener.com
Certain Common Stock of Nuvectis Pharma, Inc. are subject to a Lock-Up Agreement Ending on 13-AUG-2026. - marketscreener.com
Nuvectis Pharma (NVCT) Holds Near $18.88 as Shares Consolidate Between Support and ResistanceWave Truncation - dars.gov.et
NVCT Q1 2026 Earnings: Narrower-Than-Expected Loss Reflects Cost Discipline Amid Ongoing Clinical DevelopmentPerformance Review - careplusvn.com
StreetWatch: Nuvectis Pharma Eyes $9.8 Billion Oral PNH Market Wi - The National Law Review
Nuvectis Pharma Inc Azioni (NVCT) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Nuvectis Pharma Inc Azioni (NVCT) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| BENTSUR RON | Chairman & CEO |
Jun 30 '26 |
Buy |
20.00 |
12,500 |
250,000 |
3,688,424 |
| BENTSUR RON | Chairman & CEO |
Nov 05 '25 |
Buy |
5.72 |
5,000 |
28,600 |
3,525,924 |
| Sanchez Juan | Director |
Nov 05 '25 |
Buy |
5.79 |
13,000 |
75,270 |
78,150 |
| Kaplan Matthew L. | Director |
Nov 05 '25 |
Buy |
5.84 |
11,000 |
64,240 |
124,760 |
| Mosseri Marlio Charles | 10% Owner |
Oct 27 '25 |
Buy |
6.28 |
72,836 |
457,410 |
3,136,576 |
| Mosseri Marlio Charles | 10% Owner |
Oct 23 '25 |
Buy |
6.06 |
46,900 |
284,214 |
3,028,706 |
| Mosseri Marlio Charles | 10% Owner |
Oct 24 '25 |
Buy |
6.15 |
35,034 |
215,459 |
3,063,740 |
0.05%
0.82%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):